Avalo Therapeutics, Inc.
AVTX
$18.79
$1.8210.73%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -76.59% | -45.35% | -69.59% | -77.09% | -63.56% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -76.59% | -45.35% | -69.59% | -77.09% | -63.56% |
| Cost of Revenue | 215.88% | 632.36% | 288.66% | 53.56% | -31.41% |
| Gross Profit | -241.55% | -808.84% | -421.78% | -84.91% | 25.66% |
| SG&A Expenses | 47.09% | 57.57% | 81.66% | 67.37% | 38.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 107.54% | 163.39% | 137.95% | 62.85% | 4.33% |
| Operating Income | -112.37% | -170.98% | -153.09% | -74.34% | -9.68% |
| Income Before Tax | -1,151.78% | -27.29% | 151.19% | -11.05% | 75.97% |
| Income Tax Expenses | 1,755.56% | 853.85% | 784.62% | 714.29% | -129.03% |
| Earnings from Continuing Operations | -1,155.06% | -27.59% | 151.10% | -11.37% | 76.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1,155.06% | -27.59% | 151.10% | -11.37% | 76.02% |
| EBIT | -112.37% | -170.98% | -153.09% | -74.34% | -9.68% |
| EBITDA | -112.08% | -171.15% | -153.76% | -74.80% | -9.75% |
| EPS Basic | 77.93% | 91.69% | 98.68% | 91.31% | 93.59% |
| Normalized Basic EPS | 91.70% | 98.21% | 101.30% | 72.32% | 82.92% |
| EPS Diluted | 84.98% | 88.56% | 94.81% | 89.34% | 90.58% |
| Normalized Diluted EPS | 91.86% | 96.73% | 100.59% | 71.79% | 82.60% |
| Average Basic Shares Outstanding | 48.94% | 47.02% | 2,487.66% | 3,508.12% | 8,868.64% |
| Average Diluted Shares Outstanding | 27.17% | 67.77% | 2,760.47% | 3,980.28% | 10,403.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |